Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Uitdehaag, Joost C M ^a   De Roos, Jeroen A D M ^a   Van Doornmalen, Antoon M ^a   Prinsen, Martine B W ^a   De Man, Jos ^a   Tanizawa, Yoshinori ^b   Kawase, Yusuke ^b   Yoshino, Kohichiro ^b   Buijsman, Rogier C ^a   Zaman, Guido J R ^a  

^a Netherlands Translational Research Center BV ^*  (Netherlands)

^b 1 5 5 Minatojima Minamimachi   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABL1 INHIBITOR; AFATINIB; AXITINIB; B RAF KINASE INHIBITOR; BORTEZOMIB; BOSUTINIB; CABOZANTINIB; CRIZOTINIB; DABRAFENIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; FASUDIL; GEFITINIB; IMATINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NILOTINIB; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; PONATINIB; REGORAFENIB; RUXOLITINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOFACITINIB; TRAMETINIB; UNCLASSIFIED DRUG; VANDETANIB; VEMURAFENIB; GENETIC MARKER; PROTEIN KINASE INHIBITOR; PROTEOME;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOCHEMISTRY; BRAIN VASOSPASM; CELL GROWTH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; IC 50; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MYELOFIBROSIS; ONCOGENE; RHEUMATOID ARTHRITIS; THYROID MEDULLARY CARCINOMA; TUMOR SUPPRESSOR GENE; ANALYSIS OF VARIANCE; CHEMISTRY; COMPARATIVE STUDY; GENETIC MARKER; GENETICS; METABOLISM; NEOPLASMS; REPRODUCIBILITY;

ANALYSIS OF VARIANCE; GENE TARGETING; GENETIC MARKERS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEOME; REPRODUCIBILITY OF RESULTS;

EID: 84901281392     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092146     Document Type: Article

References (55)

1. Mullard A (2013) FDA drug approvals. Nature Rev Drug Disc 12: 87-90.
2. Simon R, Roychowdbury S (2013) Implementing personalized cancer genomics in clinical trials. Nature Rev Drug Disc 12: 358-369.
3. Hanahan D,Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
4. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575.
5. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. (2013) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
6. Greshock J, Bachman KE, Degenhardt YY, Jing J, Wen YH, et al. (2010) Molecular target class is predictive of in vitro response profile. Cancer Res 70: 3677-3686.
7. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, et al. (2007) Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 104: 19936-19941.
8. Sharma SV, Haber DA, Settleman J (2010) Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature Rev Cancer 10: 241-253.
9. Shoemaker RH (2006) The NCI human tumour cell line anticancer screen. Nature Rev Cancer 6: 813-823.
10. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, et al.(2002) An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62: 1139-1147. (Pubitemid 34160300)
11. Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, et al. (2013) Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes to cells 18: 110-122.
12. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, et al. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nature Biotechnol 29: 1046-1051.
13. Metz J, Johnson EF, Soni NB, Merta PJ, Kifle L, et al. (2011) Navigating the kinome. Nature Chem Biol 7: 200-202.
14. Uitdehaag JCM, Verkaar FA, Alwan H, de Man J, Buijsman RC, et al. (2012) A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Br J Pharmacol 166: 858-876.
15. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, et al. (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10: 2298-2308.
16. King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, et al. (2013) Dabrafenib, preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLOS One 8, e67583.
17. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, et al. (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16: 401-412 (2009).
18. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, et al. (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129: 245-255.
19. Yoshida T, Kakegawa J, Yamaguchi T, Hantani Y, Okajima N, et al. (2012) Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2. Oncotarget 3: 1533-1545.
20. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, et al. (2010) The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 107: 14903-14908.
21. Kalliokoski T, Kramer C, Vulpetti A, Gedeck P (2013) Comparability of mixed IC50 data - a statistical tool. PLOS One 8, e61007.
22. Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK (2013) Metrics other than potency reveal systematic variation in responses to cancer drugs. Nature Chem Biol 9: 708-714.
23. Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, et al. (2013). Inconsistency in large pharmacogenomic studies. Nature 504: 389-393.
24. Chou T-C, Depew KM, Zheng Y-H, Safer ML, Chan D, et al. (1998) Reversal of anticancer multidrug resistance by the ardeemins. Proc Natl Acad Sci USA 95: 8369-8374. (Pubitemid 28326119)
25. Chen TR, Dorotinsky CS, McGuire LJ, Macy ML, Hay RJ (1995) DLD-1 and HCT-15 cell lines derived separately from colorectal carcinomas have totally different chromosome changes but the same genetic origin. Cancer Genet Cytogenet 81: 103-108.
26. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, et al. (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nature Struct Mol Biol 11: 1192-1197.
27. Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, et al. (2013) Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer 49: 3412-3419.
28. Bentzien F, Zuzow M, Heald N, Gibson A, Shi Y, et al. (2013) In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET and VEGFR2, in a model of medullary thyroid cancer Thyroid. 2013 Sep 17 [epub ahead of print].
29. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nature Reviews Cancer 12: 89-103.
30. Bain J, Plater L, Elliott M, Shapiro N, Hastie CJ, et al. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315.
31. Bamborough P (2012) System-based drug discovery within the human kinome. Expert Opin Drug Discovery 7: 1053-1070.
32. Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G (2012) Targeting cancer with small-molecular weight kinase inhibitors. Methods in Mol Biol 795: 1-34.
33. Uitdehaag JCM, Zaman GJ (2011) A theoretical entropy score as a single value to express inhibitor selectivity. BMC Bioinformatics 12: 94.
34. Li JJ, Liu DP, Liu GT, Xie D (2009) Ephrin A5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor. Oncogene 28: 1759-1768.
35. Wilhelm S, Chien DS (2002) BAY 43-9006: preclinical data. Curr Pharm Design 8: 2255-2257. (Pubitemid 35189898)
36. Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors Nature Rev Cancer 9: 28-39.
37. Prahallad A, Sun C, Huang S, Nicolantonio F, Salazar R, et al. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483: 100-103.
38. Knight ZA, Lin H, Shokat KM (2010) Targeting the cancer kinome through polypharmacology. Nature Rev Cancer 10: 130-137.
39. Morphy R (2010) Selectively nonselective kinase inhibition: striking the right balance. J Med Chem 53: 1413-1437.
40. Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B (2013) Objective assessment of cancer genes for drug discovery. Nature Rev Drug Disc 12: 35-50.
41. Jeong W-J, Yoon J, Park JC, Lee SH, Kaduwal S, et al. (2012) Ras stabilization through aberrant activation of Wnt/β-catenin signaling promotes intestinal tumorigenesis. Science Signaling 5: ra30.
42. Gosens R, Baarsma HA, Heijink IH, Oenema TA, Halayko AJ, et al. (2010) De novo stabilization of β-catenin via H-Ras and MEK regulates airway smooth muscle growth. The FASEB J 24: 757-768.
43. Zhao S, Wang Y, Cao L, Ouellette MM, Freeman JW (2010) Expression of oncogenic K-ras and loss of Smad4 cooperate to induce the expression of EGFR and to promote invasion of immortalized human pancreas ductal cells. Int J Cancer 127: 2076-2086.
44. Mimori K, Yamashita K, Ohta M, Yoshinaga K, Ishikawa K, et al. (2004) Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7 expressing cancer cells. Clin Cancer Res 10, 8243-8249. (Pubitemid 40053384)
45. Greuber EK, Smith-Pearson P, Wang J, Pendergast AM (2013) Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nature Rev Cancer 13: 559-571.
46. Colicelli J (2010) ABL tyrosine kinases: evolution of function, regulation and specificity. Sci Signal 3: (139) re6.
47. Ganguly SS, Fiore LS, Sims JT, Friend JW, Srinivasan D (2012) c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. Oncogene 31: 1804-1816.
48. R development core team (2008) R: a language and environment for statistical computing. R Foundation for statistical computing, Vienna, Austria.
49. Ward JH Jr (1963) Hierarchical grouping to optimize an objective function. J Am Stat Assoc 58: 236-244.
50. Jain AK, Murty MN, Flynn PJ (1999) Data clustering: a review. ACM computing surveys 31: 264-322.
51. Koos B, Jeibmann A, Lünenbürger H, Mertsch S, Nupponen NN (2010) The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical tertoid and malignant rhabdoid tumors. Cancer 116: 5075-5081.
52. McGahon AJ, Brown DG, Martin SJ, Amarante-Mendes GP, Cotter TG, et al. (1997) Downregulation of Bcr-Abl in K562 cells restores susceptibility to apoptosis: characterization of the apoptotic death. Cell Death Differ 4: 95-104. (Pubitemid 27064875)
53. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statistic Soc B 57: 289-300.
54. Gubler H, Schopfer U, Jacoby E (2013) Theoretical and experimental relationships between percent inhibition and IC50 data observed in high-throughput screening. J Biomol Screen 18: 1-13.
55. Sedrani R, Cottens S, Kallen J, Schuler W (1998) Chemical modification of rapamycin: the discovery of SDZ RAD. Transplantation proceedings 30: 2192-2194. (Pubitemid 28399473)